| Name | Title | Contact Details |
|---|
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
Coventry Court Health Ctr is a Anaheim, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Whisper Hearing Center is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ATS Health Services is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Atrium Health, previously Carolinas HealthCare System, one of the nation`s leading and most innovative healthcare organizations, provides a full spectrum of healthcare and wellness programs throughout the Southeast region. Its diverse network of care locations includes academic medical centers, hospitals, freestanding emergency departments, physician practices, surgical and rehabilitation centers, home health agencies, nursing homes and behavioral health centers, as well as hospice and palliative care services. Atrium Health works to enhance the overall health and well-being of its communities through high-quality patient care, education and research programs, and numerous collaborative partnerships and initiatives. Our mission: to improve health, elevate hope and advance healing – for all. Premier facilities include Levine Cancer Institute, Levine Children`s Hospital, Sanger Heart & Vascular Institute, and the Neurosciences Institute. Ultimately, our success is determined not by the buildings we construct, but by the investment we make in the people and programs that bring each new facility to life. We are providing a broad framework of support that enables extraordinary professionals to bring caring, commitment, integrity and teamwork to a vitally important healing mission. The motivating force behind all of this activity is fulfilling our duty to meet community needs.